[go: up one dir, main page]

MX2022005867A - Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2 -metilfenil)piridin-3-amina, un intermediario clave de nt-814. - Google Patents

Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2 -metilfenil)piridin-3-amina, un intermediario clave de nt-814.

Info

Publication number
MX2022005867A
MX2022005867A MX2022005867A MX2022005867A MX2022005867A MX 2022005867 A MX2022005867 A MX 2022005867A MX 2022005867 A MX2022005867 A MX 2022005867A MX 2022005867 A MX2022005867 A MX 2022005867A MX 2022005867 A MX2022005867 A MX 2022005867A
Authority
MX
Mexico
Prior art keywords
fluoro
pyridin
chloro
methylphen
amine
Prior art date
Application number
MX2022005867A
Other languages
English (en)
Inventor
Marcel Schleusner
Massimo Ghizzoni
Ron Lawrence
Original Assignee
Kandy Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kandy Therapeutics Ltd filed Critical Kandy Therapeutics Ltd
Publication of MX2022005867A publication Critical patent/MX2022005867A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44Palladium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a un nuevo proceso para la producción de compuesto 2-(3,5-bis(trifluorometil)fenil)-N-(6-cloro-4-(4-fluoro- 2-metilfenil)piridin-3-il)-N,2-dimetilpropa-namida (Compuesto IX), que es útil en la elaboración de Compuesto 2-[3,5-Bis(trifluorome-til)fenil]-N-{4-(4-fluoro-2-metilfenil)-6- [(7S,9aS)-7-(hidroximetil)hexahidropirazino[2,1-c][1,4]oxazin-8(1 H)-il]-3-piridinil}-N,2-dimetilpropanamida (Compuesto A).
MX2022005867A 2019-11-15 2020-11-09 Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2 -metilfenil)piridin-3-amina, un intermediario clave de nt-814. MX2022005867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19209562 2019-11-15
PCT/EP2020/081476 WO2021094247A1 (en) 2019-11-15 2020-11-09 New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814

Publications (1)

Publication Number Publication Date
MX2022005867A true MX2022005867A (es) 2022-06-14

Family

ID=68583265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005867A MX2022005867A (es) 2019-11-15 2020-11-09 Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2 -metilfenil)piridin-3-amina, un intermediario clave de nt-814.

Country Status (17)

Country Link
US (1) US12473260B2 (es)
EP (1) EP4058433A1 (es)
JP (1) JP7673064B2 (es)
KR (1) KR20220101090A (es)
CN (2) CN114728906B (es)
AR (1) AR120468A1 (es)
AU (1) AU2020381762A1 (es)
CA (1) CA3161336A1 (es)
CL (1) CL2024002310A1 (es)
CO (1) CO2022006071A2 (es)
CR (1) CR20220213A (es)
IL (1) IL292921A (es)
JO (1) JOP20220111A1 (es)
MX (1) MX2022005867A (es)
PE (1) PE20221167A1 (es)
TW (1) TWI874486B (es)
WO (1) WO2021094247A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019175253A1 (en) 2018-03-14 2019-09-19 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
DE602004008631T2 (de) 2003-07-03 2008-07-10 F. Hoffmann-La Roche Ag Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
JP2005064075A (ja) * 2003-08-20 2005-03-10 Toshiba Corp 磁気記憶装置及びその製造方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
KR20070017732A (ko) * 2005-08-08 2007-02-13 삼성전자주식회사 드럼 세탁기
MY145713A (en) * 2005-09-09 2012-03-30 Smithkline Beecham Corp Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders
LT2656841T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
BR112012003435A2 (pt) * 2009-08-27 2016-02-23 Glaxosmithkline Llc formas anidras de um derivado de píridina
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
ES2671418T3 (es) 2013-11-08 2018-06-06 Kissei Pharmaceutical Co., Ltd. Derivado de carboximetilpiperidina
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
BR112017008393A2 (pt) * 2014-10-22 2017-12-19 Ibis Biosciences Inc aparelho e sistema para amplificação de ácido nucleico
CN114306335A (zh) * 2015-05-18 2022-04-12 康堤医疗有限公司 用于治疗性激素依赖性疾病的双重nk-1/nk-3受体拮抗剂
WO2019175253A1 (en) 2018-03-14 2019-09-19 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists

Also Published As

Publication number Publication date
JP7673064B2 (ja) 2025-05-08
WO2021094247A1 (en) 2021-05-20
CL2024002310A1 (es) 2024-11-08
AU2020381762A1 (en) 2022-06-02
EP4058433A1 (en) 2022-09-21
TW202128625A (zh) 2021-08-01
JP2023501666A (ja) 2023-01-18
TWI874486B (zh) 2025-03-01
CA3161336A1 (en) 2021-05-20
US20230002322A1 (en) 2023-01-05
CO2022006071A2 (es) 2022-05-20
AR120468A1 (es) 2022-02-16
US12473260B2 (en) 2025-11-18
PE20221167A1 (es) 2022-07-25
IL292921A (en) 2022-07-01
JOP20220111A1 (ar) 2023-01-30
KR20220101090A (ko) 2022-07-19
CN114728906B (zh) 2024-08-20
CN114728906A (zh) 2022-07-08
CR20220213A (es) 2022-07-08
CN118496152A (zh) 2024-08-16

Similar Documents

Publication Publication Date Title
CL2024002310A1 (es) Nuevo proceso químico para la elaboración de 6–cloro–4–(4–fluoro–2–metilfenil)piridin–3–amina, un intermediario clave de nt–814
NZ594776A (en) Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
IL283333B1 (en) Heterocyclic monoacylglycerol lipase inhibitors, processes for their manufacture, pharmaceutical compositions comprising them and their uses in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and mental disorders
PE20140832A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
PE20061120A1 (es) Compuesto de heteroarilo como inhibidores del receptor p2y1
HRP20110457T1 (hr) Derivati piridina i njihova upotreba u liječenju psihotičnih poremećaja
PE20011287A1 (es) Derivados de imidazopirimidina y derivados de triazolopirimidina
PE20120110A1 (es) [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20170004A1 (es) Inhibidores de biaril cinasa
NZ626394A (en) Substituted annulated pyrimidines and triazines, and use thereof
NZ628583A (en) 6 - alkynyl pyridines as smac mimetics
JP2018537408A5 (es)
MX2014002092A (es) Derivados de isoxazolina como compuestos insecticidas.
EA200870586A1 (ru) 3-(1,3-бензодиоксол-5-ил)-6-(4-циклопропилпиперазин-1-ил)пиридазин, его соли и сольваты и его применение в качестве антагониста н3 рецептора гистамина
SG10201810057UA (en) Crystalline fgfr4 inhibitor compound and uses thereof
JOP20200227A1 (ar) تركيبة صيدلانية جديدة تشتمل على مضادات مستقبلة ثنائية من نيوروكينين-1/نيوروكينين-3
MX377921B (es) Proceso para la preparacion de (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida
ZA202106014B (en) Solid forms of condensed pyrazines as syk inhibitors
NO20061137L (no) Cyklopropylderivater som NK3-reseptorantagonister
PE20160040A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
MY169128A (en) Pd-catalyzed coupling of pyrazole amides
PE20190204A1 (es) [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas
HK1207643A1 (en) Amides of 2-amino-4-arylthiazole compounds and their salts